Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Fosfomycin resistance mechanisms in Enterobacterales: an increasing threat

V. Mattioni Marchetti, J. Hrabak, I. Bitar

. 2023 ; 13 (-) : 1178547. [pub] 20230704

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016924

Antimicrobial resistance is well-known to be a global health and development threat. Due to the decrease of effective antimicrobials, re-evaluation in clinical practice of old antibiotics, as fosfomycin (FOS), have been necessary. FOS is a phosphonic acid derivate that regained interest in clinical practice for the treatment of complicated infection by multi-drug resistant (MDR) bacteria. Globally, FOS resistant Gram-negative pathogens are raising, affecting the public health, and compromising the use of the antibiotic. In particular, the increased prevalence of FOS resistance (FOSR) profiles among Enterobacterales family is concerning. Decrease in FOS effectiveness can be caused by i) alteration of FOS influx inside bacterial cell or ii) acquiring antimicrobial resistance genes. In this review, we investigate the main components implicated in FOS flow and report specific mutations that affect FOS influx inside bacterial cell and, thus, its effectiveness. FosA enzymes were identified in 1980 from Serratia marcescens but only in recent years the scientific community has started studying their spread. We summarize the global epidemiology of FosA/C2/L1-2 enzymes among Enterobacterales family. To date, 11 different variants of FosA have been reported globally. Among acquired mechanisms, FosA3 is the most spread variant in Enterobacterales, followed by FosA7 and FosA5. Based on recently published studies, we clarify and represent the molecular and genetic composition of fosA/C2 genes enviroment, analyzing the mechanisms by which such genes are slowly transmitting in emerging and high-risk clones, such as E. coli ST69 and ST131, and K. pneumoniae ST11. FOS is indicated as first line option against uncomplicated urinary tract infections and shows remarkable qualities in combination with other antibiotics. A rapid and accurate identification of FOSR type in Enterobacterales is difficult to achieve due to the lack of commercial phenotypic susceptibility tests and of rapid systems for MIC detection.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016924
003      
CZ-PrNML
005      
20231026105448.0
007      
ta
008      
231013s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fcimb.2023.1178547 $2 doi
035    __
$a (PubMed)37469601
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mattioni Marchetti, Vittoria $u Department of Microbiology, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czechia $u Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czechia $u Unit of Microbiology and Clinical Microbiology, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
245    10
$a Fosfomycin resistance mechanisms in Enterobacterales: an increasing threat / $c V. Mattioni Marchetti, J. Hrabak, I. Bitar
520    9_
$a Antimicrobial resistance is well-known to be a global health and development threat. Due to the decrease of effective antimicrobials, re-evaluation in clinical practice of old antibiotics, as fosfomycin (FOS), have been necessary. FOS is a phosphonic acid derivate that regained interest in clinical practice for the treatment of complicated infection by multi-drug resistant (MDR) bacteria. Globally, FOS resistant Gram-negative pathogens are raising, affecting the public health, and compromising the use of the antibiotic. In particular, the increased prevalence of FOS resistance (FOSR) profiles among Enterobacterales family is concerning. Decrease in FOS effectiveness can be caused by i) alteration of FOS influx inside bacterial cell or ii) acquiring antimicrobial resistance genes. In this review, we investigate the main components implicated in FOS flow and report specific mutations that affect FOS influx inside bacterial cell and, thus, its effectiveness. FosA enzymes were identified in 1980 from Serratia marcescens but only in recent years the scientific community has started studying their spread. We summarize the global epidemiology of FosA/C2/L1-2 enzymes among Enterobacterales family. To date, 11 different variants of FosA have been reported globally. Among acquired mechanisms, FosA3 is the most spread variant in Enterobacterales, followed by FosA7 and FosA5. Based on recently published studies, we clarify and represent the molecular and genetic composition of fosA/C2 genes enviroment, analyzing the mechanisms by which such genes are slowly transmitting in emerging and high-risk clones, such as E. coli ST69 and ST131, and K. pneumoniae ST11. FOS is indicated as first line option against uncomplicated urinary tract infections and shows remarkable qualities in combination with other antibiotics. A rapid and accurate identification of FOSR type in Enterobacterales is difficult to achieve due to the lack of commercial phenotypic susceptibility tests and of rapid systems for MIC detection.
650    12
$a fosfomycin $x farmakologie $7 D005578
650    _2
$a Escherichia coli $x genetika $7 D004926
650    _2
$a bakteriální léková rezistence $x genetika $7 D024881
650    _2
$a antibakteriální látky $x farmakologie $7 D000900
650    12
$a proteiny z Escherichia coli $x genetika $7 D029968
650    _2
$a Klebsiella pneumoniae $x genetika $7 D007711
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hrabak, Jaroslav $u Department of Microbiology, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czechia $u Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czechia
700    1_
$a Bitar, Ibrahim $u Department of Microbiology, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czechia $u Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czechia
773    0_
$w MED00182987 $t Frontiers in cellular and infection microbiology $x 2235-2988 $g Roč. 13, č. - (2023), s. 1178547
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37469601 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105443 $b ABA008
999    __
$a ok $b bmc $g 2000447 $s 1203286
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c - $d 1178547 $e 20230704 $i 2235-2988 $m Frontiers in cellular and infection microbiology $n Front Cell Infect Microbiol $x MED00182987
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...